GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b also ...
Cure Today2h
Lumakras Combo May Replace SOC in Third-Line Treatment for mCRC
Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...
Targeted Oncology8h
FDA Grants Key Oncology Approvals and Designations in January 2025
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Verastem CEO Dan Paterson sells shares worth $4,890
Dan Paterson, President and CEO of Verastem, Inc. (NASDAQ:VSTM), a clinical-stage biopharmaceutical company with a market capitalization of $273 million, recently sold 858 shares of the company's ...